

# Francesco Saglio



## WORK EXPERIENCE

### Member of the Phase I Clinical Trials Unit

*SC Oncoematologia Pediatrica – Ospedale Infantile Regina Margherita – AOU Città della Salute e della Scienza di Torino* [ 05/2017- Current ]

### MD Paediatrics

*SC Oncoematologia Pediatrica – Ospedale Infantile Regina Margherita – AOU Città della Salute e della Scienza di Torino* [ 2015 – Current ]

### MD Paediatrics -

*DEA - Ospedale Infantile Regina Margherita – AOU Città della Salute e della Scienza di Torino* [ 2014-2015 ]

## EDUCATION AND TRAINING

### PhD in Biomedical Sciences and Oncology

*University of Turin* [ 2018 ]

### Post Doctoral Fellowship

*Baylor College of Medicine , Houston – Texas, US* [ 2007

### Specialization in Paediatrics

*University of Turin* [ 2014 ]

### Medical Degree

*University of Turin* [ 2007 ]

## JOB-RELATED SKILLS

### Job-related skills

Many years of experience in conduction clinical studies in accordance with Good Clinical Practices

I am subinvestigator in the following clinical trials

- A Phase III, randomized, open-label, multicentre study with ruxolitinib versus the best available therapy in patients with chronic corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation " - REACH 3
- A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients -SHP 620 320
- A Phase I study on the safety, pharmacokinetics and efficacy of infusion of BPX-501 cells from donors and AP1903 in children with recurrent malignant haematological diseases or minimal residual disease after allogeneic transplant - BPI008

- A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD) -PCYC-1140-IM
- Studio Clinico di Fase 1 sull'utilizzo di immunoterapia adottiva con cellule Cytokine Induced Killer (CIK) autologhe in pazienti con diagnosi di sarcoma avanzato non operabile recidivato/refrattario alle terapie convenzionali - C.A.S.T.

## **OTHER RELEVANT EXPERIENCE**

### **Other Relevant Experience**

2016- present : Member of GdL AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) TCSE e terapia cellulare

2018- present Member of GITMO (Gruppo Italiano Trapianto Midollo Osseo) Commissione Allogeneico

## **PRIVACY**

I authorize the processing of my personal data according to Legislative Decree 30 June 2003, n. 196 "Codice in materia di protezione dei dati personali" and of GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali", Art. 13

Given that I am aware of the criminal responsibilities provided by art. 76 of D.P.R. 445/2000 for the hypothesis of falsehood in acts and false statements, I declare that the information reported above is true.

